Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

August 31, 2006

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ISIS 113715

Trial Locations (10)

109125

Chair of Endocrinology and Diabetology of the Faculty of Advenced Training for Physicians, Moscow

117036

Endocrinology Scientific Centre of RAMS, Moscow

117420

"Medical Institution Polyclinic OAOA Gazprom", Moscow

123056

"Close Corporation MEDSI", Moscow

125315

Chair of Endocrinology and Diabetology Central Clinical Hospital of the Ministry of Communications of RF, Moscow

129110

Moscow Regional Scientific-Research Clinical Institute named after I.F. Vladimirsky, Moscow

198013

Clinic of Therapy of Postgraduate Education named after N.S. Molchanov, Saint Petersburg

15-435

NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny, Bialystok

26-600

Prywatna Praktyka Lekarska, Radom

05-200

Oddzial Chorob Wewnetrznych ze Stacja Dializ Szpital w Wolominie, Wołomin

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY